Beyond Excipients: Cyclodextrins Are Now Recognized as Active Therapeutic Agents in Their Own Right

For decades, cyclodextrins were valued primarily as pharmaceutical excipients — inactive ingredients used to improve drug solubility and stability. A landmark 2025 review published in Pharmaceuticals argues that this characterization is outdated.

The paper documents growing evidence that cyclodextrins possess intrinsic biological activity, including the ability to interact directly with cell membranes, mobilize cholesterol from lipid rafts, and modulate immune responses. These properties open entirely new therapeutic avenues.

Researchers have demonstrated that cyclodextrins can influence receptor clustering within cell membranes, triggering specific intracellular signaling pathways that have implications for treating cardiovascular disease, viral infections, and metabolic disorders. Cationic cyclodextrin derivatives are also being developed for gene and mRNA delivery.

With over 120 cyclodextrin-based pharmaceutical products already on the market worldwide and dozens more in clinical trials, this shift from passive carrier to active agent represents a significant expansion of what cyclodextrins can contribute to modern medicine.